These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 11926700

  • 1. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
    Bown RL.
    Int J Clin Pract; 2002 Mar; 56(2):132-9. PubMed ID: 11926700
    [Abstract] [Full Text] [Related]

  • 2. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E.
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [Abstract] [Full Text] [Related]

  • 3. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C.
    Clin Ther; 1993 Mar; 15 Suppl B():14-21. PubMed ID: 7911399
    [Abstract] [Full Text] [Related]

  • 4. Lansoprazole: a comprehensive review.
    Zimmermann AE, Katona BG.
    Pharmacotherapy; 1997 Mar; 17(2):308-26. PubMed ID: 9085323
    [Abstract] [Full Text] [Related]

  • 5. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI, Goa KL.
    Drugs; 2001 Mar; 61(15):2327-56. PubMed ID: 11772142
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ, Hunt RH.
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [Abstract] [Full Text] [Related]

  • 7. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
    Güliter S, Keleş H, Ozkurt ZN, Cengiz DU, Kolukisa E.
    Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
    [Abstract] [Full Text] [Related]

  • 8. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD, Wilde MI.
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [Abstract] [Full Text] [Related]

  • 9. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C.
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [Abstract] [Full Text] [Related]

  • 10. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
    Hirschowitz BI, Mohnen J, Shaw S.
    Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
    [Abstract] [Full Text] [Related]

  • 11. Pharmacotherapy for acid/peptic disorders.
    Schubert ML.
    Yale J Biol Med; 1996 Aug; 69(2):197-201. PubMed ID: 9112751
    [Abstract] [Full Text] [Related]

  • 12. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K, Hashimoto T, Komazawa Y, Mihara T, Furuta K, Fujishiro H, Ishihara S, Amano Y, Hattori S, Kinoshita Y.
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [Abstract] [Full Text] [Related]

  • 13. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ, Jarvis B.
    Drugs; 2001 Jul; 61(12):1801-33. PubMed ID: 11693467
    [Abstract] [Full Text] [Related]

  • 14. Lansoprazole: a proton pump inhibitor.
    Garnett WR.
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [Abstract] [Full Text] [Related]

  • 15. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
    Gremse DA.
    Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
    [Abstract] [Full Text] [Related]

  • 16. Clinical review of lansoprazole.
    Lockhart SP.
    Br J Clin Pract Suppl; 1994 Oct; 75():48-55; discussion 56-7. PubMed ID: 8060802
    [Abstract] [Full Text] [Related]

  • 17. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD, Markham A.
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [Abstract] [Full Text] [Related]

  • 18. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM, Prakash A, Faulds D, Lamb HM.
    Drugs; 2003 Oct; 63(1):101-33. PubMed ID: 12487624
    [Abstract] [Full Text] [Related]

  • 19. [25 years of gastric acid blockers].
    Lamers CB.
    Ned Tijdschr Geneeskd; 1999 Dec 11; 143(50):2501-4. PubMed ID: 10627749
    [Abstract] [Full Text] [Related]

  • 20. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M, Pospai D, Forestier S, Vatier J, Vallot T.
    Clin Ther; 1993 Dec 11; 15 Suppl B():22-31. PubMed ID: 8205592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.